A
A.S. Jung
Researcher at Amgen
Publications - 6
Citations - 300
A.S. Jung is an academic researcher from Amgen. The author has contributed to research in topics: Panitumumab & Neuroblastoma RAS viral oncogene homolog. The author has an hindex of 4, co-authored 6 publications receiving 250 citations.
Papers
More filters
Journal ArticleDOI
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Pei He,Hua Yu,Reija Koukakis,Jan Henrik Terwey,A.S. Jung,Roger Sidhu,Scott D. Patterson +22 more
TL;DR: Findings support RAS testing for patients with mCRC and the benefit–risk of panitumumab–FOLFIRI was improved in the wild-type RAS population compared with theWild-type KRAS exon 2 population.
Journal ArticleDOI
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
Salvatore Siena,Andrea Sartore-Bianchi,Rocio Garcia-Carbonero,M. Karthaus,D. Smith,Josep Tabernero,E. Van Cutsem,Xuesong Guan,Michael Boedigheimer,A. Ang,Brian Twomey,Bruce A. Bach,A.S. Jung,Alberto Bardelli +13 more
TL;DR: This first prospective analysis in mCRC showed that serial plasma biopsies are more inclusive than tissueBiopsies for evaluating global tumor heterogeneity; however, the clinical utility of plasma testing in m CRC remains to be further explored.
Journal ArticleDOI
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Hua Yu,A.S. Jung,Roger Sidhu,Scott D. Patterson +19 more
TL;DR: Extended RAS analysis from this study showed a trend toward improvements in HR on OS and PFS with pmab + FOLFIRI vs F OLFIRI in WT RAS group vs WT KRAS exon 2 group.
Journal ArticleDOI
Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor-Eliade Ciuleanu,Laslo Roman,Eric Van Cutsem,Ying Tian,A.S. Jung,Roger Sidhu,Scott D. Patterson +19 more
TL;DR: This prospective retrospective analysis of 1st-line mCRC PRIME study showed that mutations in RAS genes (KRAS/NRAS exons 2/3/4) predicted a lack of response to pmab, so the primary objective was to assess the tx effect of pmab + FOLFIRI vs F OLFIRI on OS and PFS based on RAS mutation status in the primary analysis population.
Journal ArticleDOI
Pd-0002kras/nras and braf mutations in the 20050181 study of panitumumab + folfiri for the 2nd-line treatment of metastatic colorectal cancer: updated analysis
Monika Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,T. Andre,Emily Chan,Florian Lordick,C.J.A. Punt,A. H. Strickland,Gregory C. Wilson,Tudor-Eliade Ciuleanu,Laslo Roman,E. Van Cutsem,Hua Yu,A.S. Jung,Roger Sidhu,Scott D. Patterson +19 more